ABSTRACT

There are inherent difficulties in the use of science by the rules of the World Trade Organization (WTO) to mediate the conflict between free trade and non-trade concerns in the area of health. These are most clearly illustrated by the long-awaited decision of the WTO Panel in the EC – Biotech Products 1 dispute.